Immunogenicity and safety of co-immunization with 23-valent pneumococcal polysaccharide vaccine and influenza virus split vaccine for children aged 3-7 years

Zhiguo Wang; Xiang Sun; Min Zhang; Fenyang Tang; Fubao MA; Yan XU; Ran HU; Yanli MA; Yanhui Xiao; Haiping Chen; Linyun Luo

Return

Immunogenicity and safety of co-immunization with 23-valent pneumococcal polysaccharide vaccine and influenza virus split vaccine for children aged 3-7 years

VernacularTitle: 3～7岁儿童同时接种23价肺炎球菌多糖疫苗和流感病毒裂解疫苗的免疫原性及安全性研究
Author: Zhiguo WANG ¹ ; Xiang SUN ¹ ; Min ZHANG ² ; Fenyang TANG ¹ ; Fubao MA ¹ ; Yan XU ¹ ; Ran HU ¹ ; Yanli MA ² ; Yanhui XIAO ² ; Haiping CHEN ² ; Linyun LUO ²
Author Information

1. Department of Expanded Programme on Immunization, Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing 210009, China
2. Department of Medical Affairs, Chinese Biotechnology Company Limited, Beijing 100024, China
Publication Type:Journal Article
Keywords: Pneumococcal polysaccharide vaccine (PPV23); Trivalent influenza vaccine (TIV); Preschoolers; Safety; Immunogenicity
From: Chinese Journal of Microbiology and Immunology 2019;39(10):758-762
CountryChina
Language:Chinese
Abstract: Objective:To evaluate the immunogenicity and safety of concomitant administration of 23-valent pneumococcal polysaccharide vaccine (PPV23) and trivalent influenza vaccine (TIV) in preschoolers.
Methods:A total of 1 035 children aged 3-7 years were enrolled in this study and randomly divided into three groups, inoculated PPV23, TIV and both, respectively. A one-year follow-up study was conducted for immunogenicity and safety analysis.
Results:A total of 1 035 serological specimens were collected, including 327 in PPV23 group, 348 in TIV group and 360 in concomitant vaccination group. No significant differences in geometric mean concentrations (GMC) of seven pneumococcal serotypes were observed between the PPV23 group and the concomitant vaccination group. Compared with the TIV group, the concomitant vaccination group showed higher serological conversion rate of H3 type (88.75% vs 84.20%, P=0.01), but lower serological conversion rate of B type (92.84% vs 98.56%, P<0.001). There was no significant difference in the primary adverse reactions between the three groups (P=0.197). The rate of secondary adverse reactions occurred in the concomitant vaccination group was 3.61%, which was higher than that of the other two groups (both P<0.001). All adverse reactions were mild or moderate, and cured after treatment.
Conclusions:Concomitant immunization with PPV23 and TIV is safe and have good immunogenicity, thus a viable immune strategy for susceptible children.